Skip to content

Daclatasvir impurity C

Daclatasvir impurity C

Product Description
CAT No.
ALN-D036022
CAS No.
1256385-55-3
Mol. F.
C29H32N6O3
Mol. Wt.
512.6
Stock
Please Inquire
RFQ
Chemical Name : Carbamic acid, N-​[(1S)​-​1-​[[(2S)​-​2-​[5-​[4′-​(1H-​imidazol-​5-​yl)​[1,​1′-​biphenyl]​-​4-​yl]​-​1H-​imidazol-​2-​yl]​-​1-​pyrrolidinyl]​carbonyl]​-​2-​methylpropyl]​-​, methyl ester
Smiles : O=C(N1[C@H](C2=NC=C(C3=CC=C(C4=CC=C(C5=CN=CN5)C=C4)C=C3)N2)CCC1)[C@H](C(C)C)NC(OC)=O
Inchi : InChI=1S/C35H41N7O4/c1-21(2)31(40-35(45)46-4)34(44)42-18-6-8-30(42)33-37-20-28(39-33)26-15-11-24(12-16-26)23-9-13-25(14-10-23)27-19-36-32(38-27)29-7-5-17-41(29)22(3)43/h9-16,19-21,29-31H,5-8,17-18H2,1-4H3,(H,36,38)(H,37,39)(H,40,45)/t29-,30-,31-/m0/s1

A validated stability-indicating reverse-phase high-performance liquid chromatography method for daclatasvir, identification and characterization of degradation products using LC-ESI-QTOF-MS

By Warghade, Snehal V.; Bothara, Kailash G.nFrom Asian Journal of Pharmaceutical and Clinical Research (2019), 12(5), 302-308

Development and validation of HPLC fluorescence and UPLC/DAD stability-indicating methods for determination of hepatitis C antiviral agent daclatasvir

By Kamal, Andra H.; Ismail, Nahla S.; Mabroijk, Mokhtar M.; Bebawy, Lories I.; Mekky, Mai A. – From Journal of AOAC International (2019), 102(4), 1125-1131

A stability-indicating UPLC method for the determination of potential impurities and its mass by a new QDa mass detector in daclatasvir drug used to treat hepatitis C infection

By Jagadabi, Varaprasad; Kumar, P. V. Nagendra; Mahesh, Kasthuri; Pamidi, Srinivasu; Ramaprasad, L. A.; Nagaraju, D. – From Journal of Chromatographic Science (2019), 57(1), 44-53

Request For Quotation

Related Products